DNA methyltransferase (DNMT) and PARP inhibitors induce a stimulator of IFN gene–dependent pathogen mimicry response (PMR) in ovarian and other cancers. In this study, we showed that combining DNMT and PARP inhibitors upregulates expression of the nucleic acid sensor NFX1-type zinc finger–containing 1 (ZNFX1) protein. ZNFX1 mediated the induction of PMR in mitochondria, serving as a gateway for stimulator of IFN gene–dependent IFN/inflammasome signaling. Loss of ZNFX1 in ovarian cancer cells promoted proliferation and spheroid formation in vitro and tumor growth in vivo. In patient ovarian cancer databases, expression of ZNFX1 was elevated in advanced stage disease, and ZNFX1 expression alone significantly correlated with an increase in overall survival in a phase III trial for patients with therapy-resistant ovarian cancer receiving bevacizumab in combination with chemotherapy. RNA sequencing revealed an association between inflammasome signaling through ZNFX1 and abnormal vasculogenesis. Together, this study identified that ZNFX1 is a tumor suppressor that controls PMR signaling through mitochondria and may serve as a biomarker to facilitate personalized therapy in patients with ovarian cancer. Significance: DNMT and PARP inhibitors induce a nucleic acid sensor, ZNFX1, that serves as a mitochondrial gateway to STING-dependent inflammasome signaling with tumor suppressor properties in ovarian cancer.
Breast cancers with BRCA1 or BRCA2 mutations are defective in repair of DNA double-strand breaks by homologous recombination, resulting in compensatory error-prone repair that causes genomic instability. Poly(ADP-ribose) polymerase inhibitors (PARPi) are FDA-approved to treat homologous recombination–defective cancers, inducing therapy responses by synthetic lethality. PARPis increase micronuclei formation and cytosolic double-stranded DNA accumulation, activating stimulator of interferon genes (STING). Activation of STING can mediate anticancer innate immune responses by increasing T-cell infiltration into the tumor microenvironment. However, PARPi responses are not durable, and therapy resistance ensues with limited therapeutic options available for these patients. Using PARPi-sensitive and -resistant patient-derived xenografts and mouse-derived allografts, Pedretti and colleagues show in this issue of Cancer Research that the PARPi olaparib in combination with the next-generation STING agonist diABZI can overcome PARPi resistance in a manner dependent on NK cell function in the tumor microenvironment. Their study highlights a novel component of the STING-dependent innate immune response repertoire required for fighting PARPi-resistant cancer. Potent and specific next-generation STING agonists are being tested in the clinic in solid and liquid tumors, indicating a resurgence of these drugs after a long period of modest clinical activity, with a special focus on combination therapy strategies to fight therapy-resistant cancer. See related article by Pedretti et al., p. 1888
BRCA1 has long been recognized as a guardian of genome integrity through its essential role in homologous recombination (HR)-mediated DNA repair. While HR deficiency underlies the clinical efficacy of Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), therapeutic responses remain incomplete, highlighting the need to identify vulnerabilities beyond defective DNA repair. Recent evidence has expanded the biological landscape of BRCA1, revealing critical roles in mitochondrial (mt) quality control, metabolic homeostasis, redox regulation, and innate immune signaling. Together, these functions support an integrated genome-mitochondria-immune axis through which BRCA1 coordinates cellular adaptation to stress. Disruption of this network amplifies genomic instability, promotes metabolic rewiring and inflammatory signaling, and generates vulnerabilities extending beyond HR deficiency. Mitochondrial dysfunction resulting from BRCA1 loss reinforces tumor progression through mitochondrial DNA (mtDNA) instability, oxidative stress, and tumor microenvironment remodeling while creating opportunities for therapeutic intervention. Viewing BRCA1 deficiency through this integrated framework broadens the concept of synthetic lethality and provides a rationale for combination strategies integrating PARP inhibition with mitochondrial-targeted agents, metabolic therapies, epigenetic modulators, and immune-based approaches. This perspective positions BRCA1 as a central regulator of nuclear-mitochondrial crosstalk and highlights emerging opportunities to overcome therapeutic resistance and advance precision oncology.